A Study of Oral Minoxidil to Treat Hair Loss in Children and Teens Who Are Cancer Survivors


Full Title

A Pilot Study of Oral Minoxidil for the Treatment of Persistent Hair Loss in Pediatric, Adolescent, and Young Adult Cancer Survivors


Minoxidil is a drug used to treat hair loss. It is believed to increase blood flow to hair follicles (roots) and stimulate hairs to enter the growth phase. It may be applied to the scalp, but doing so can cause irritation in some people and it may be difficult to apply consistently. In this study, researchers are assessing the use of oral minoxidil (a liquid that is swallowed) to see if it is effective in children and teens who experienced hair loss as a result of cancer treatments such as chemotherapy or radiation therapy.

Participants will be randomly assigned to one of two groups:

  • Group 1: Participants will take oral minoxidil for 8 months
  • Group 2: Participants will take a placebo for 4 months, and then oral minoxidil for the next 4 months

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have been diagnosed with cancer before age 17 and completed treatment at least 1 year before entering the study.
  • They must be experiencing hair loss for more than 6 months that is likely related to their cancer treatment.
  • This study is for people ages 6-18 years.


For more information and to see if you can join this study, please contact Dr. Alina Markova’s office at 646-608-2342.




Phase II (phase 2)



ClinicalTrials.gov ID